Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 in IDH1 Mutated Myelodysplastic Syndrome
NCT03503409Phase 2Active, not recruiting
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- May 2019
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ivosidenib in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Overall hematological response at 6 months. Started May 2019; status: active, not recruiting.
02
Drugs
ivosidenib
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03503409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503409.